JUPITER, Fla., June 30, 2011 /PRNewswire/ — Stem Cell
Assurance, Inc. (SCLZ.PK) (“SCA”) today announced the launch of
a platform technology that involves the use of brown fat for
cell-based therapeutic/cosmetic purposes. Through its brown
fat program, SCA intends to develop treatments for weight loss and
metabolic disorders. SCA will initially focus on cellular
therapies for obesity and its adverse effect on health, which could
lead to several serious and sometimes fatal diseases such as
diabetes, ischemic heart disease, stroke, hypertension and kidney
failure.
Brown fat is one of two types of known adipose (fat) tissue
found in the human body and is involved in homeostasis by creating
metabolic tissue capable of producing heat. Recent studies
have demonstrated that brown fat is present in the adult human body
and may be correlated with the maintenance and regulation of
metabolism, thus potentially being involved in caloric regulation.
SCA intends to use autologous cells (i.e., stem cells isolated
from individual patients) that may be differentiated into
progenitor or fully differentiated brown adipocytes, or a related
cell type, that can be used therapeutically or cosmetically in
patients. As the brown fat cellular program advances, SCA
will seek to determine whether data derived from the program can be
useful in developing a small molecule drug therapy.
Mark Weinreb, SCA’s Chairman and Chief Executive Officer, said,
“I am pleased to announce our first ‘flagship’ cellular platform
technology that has the potential to treat the onset of many
serious diseases, as well as provide a novel opportunity to explore
a natural ‘biological’ weight loss program. This represents a
significant step for SCA to become a leader in a field of stem cell
science that has not been saturated with exploration and is
directed to a large commercial market.”
About Stem Cell Assurance, Inc.
Stem Cell
‘/>”/>
